NCT06844799View on ClinicalTrials.gov

A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2027

Conditions
Moderate-to-severe Plaque Psoriasis
Interventions
DRUG

HS-20137

HS-20137 200mg injection at week 0, 4, 8 and then every 8 or 12 weeks.

DRUG

Placebo&HS-20137

Placebo injection at week 0, 4, 8, and then HS-20137 200mg injection at week 16, 20, 24, and every 8 or 12 weeks thereafter

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY